FAQ on Quantum BioPharma Ltd.'s $600K Private Placement and Shareholder Approval
Summary
Quantum BioPharma Ltd. is seeking shareholder approval for a $600,000 private placement of class A multiple voting shares to be used for general working capital, with the meeting scheduled for September 26, 2025.
What is Quantum BioPharma Ltd. seeking shareholder approval for?
Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600,000.
When is the annual general and special meeting for shareholder approval scheduled?
The annual general and special meeting is scheduled for September 26, 2025.
How much does Quantum BioPharma Ltd. aim to raise through this private placement?
The company aims to raise up to $600,000 through this private placement.
What will the proceeds from the private placement be used for?
The proceeds will be used for general working capital.
Are there any restrictions on the securities offered in the private placement?
Yes, all securities will be subject to a four-month-plus-one-day hold period under Canadian securities laws.
Who is expected to subscribe to the Offering?
The Offering is expected to be fully subscribed by existing class A multiple voting shares holders.
What is Quantum BioPharma Ltd.’s focus in the biopharmaceutical sector?
Quantum BioPharma Ltd. is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
What is Lucid-MS, and what is its significance?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
How does Quantum BioPharma Ltd. benefit from Unbuzzd Wellness Inc.?
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, then 3% in perpetuity.
Where can investors find the latest news and updates about Quantum BioPharma Ltd.?
The latest news and updates are available in the company’s newsroom at https://ibn.fm/QNTM.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 143625